AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby inducing apoptosis in a bcl-6-expressing cell, wherein said composition comprises a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6.

2. (Original) The method of claim 1, wherein said cell is a lymphoma cell.

3. (Original) The method of claim 2, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.

4. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition that reduces an amount of said bcl-6 protein or of a ribonucleic acid molecule encoding said bcl-6 protein, thereby treating ~~a~~ said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~, wherein said composition comprises a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6.

5. (Original) The method of claim 4, wherein said lymphoma is a non-Hodgkin's lymphoma.

6. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in a bcl-6-expressing cell.

7. (Original) The method of claim 6, wherein said cell is a lymphoma cell.

8. (Original) The method of claim 7, wherein said lymphoma cell is a non-Hodgkin's

lymphoma cell.

9. (Original) The method of claim 6, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.

10. (Cancelled).

11. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a composition comprising a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~.

12. (Original) The method of claim 11, wherein said lymphoma is a non-Hodgkin's lymphoma.

13. (Original) The method of claim 11, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.

14. (Cancelled).

15. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a composition comprising a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in a bcl-6-expressing cell.

16. (Original) The method of claim 15, wherein said cell is a lymphoma cell.

17. (Original) The method of claim 16, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.

18. (Original) The method of claim 15, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

19. (Original) The method of claim 15, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

20. (Cancelled).

21. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, said method comprising contacting said subject with a composition comprising a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~.

22. (Original) The method of claim 21, wherein said lymphoma is a non-Hodgkin's lymphoma.

23. (Original) The method of claim 21, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

24. (Original) The method of claim 21, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

25. (Cancelled).

26. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule complementary to ~~all or portion of the~~ sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in ~~a~~ said bcl-6-expressing cell.

27. (Original) The method of claim 26, wherein said cell is a lymphoma cell.

28. (Original) The method of claim 27, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.

29. (Original) The method of claim 26, wherein said vector is a lentiviral vector.

30. (Original) The method of claim 26, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.

31. (Cancelled).

32. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule complementary to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~.

33. (Original) The method of claim 32, wherein said lymphoma is a non-Hodgkin's lymphoma.

34. (Original) The method of claim 32, wherein said vector is a lentiviral vector.

35. (Original) The method of claim 32, wherein said nucleic acid molecule is an oligo-deoxyribonucleic acid (ODN) molecule.

36. (Cancelled).

37. (Currently amended) A method of inducing apoptosis in a bcl-6-expressing cell, comprising contacting said bcl-6-expressing cell with a vector expressing a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby inducing apoptosis in ~~a~~ said bcl-6-expressing cell.

38. (Original) The method of claim 37, wherein said cell is a lymphoma cell.

39. (Original) The method of claim 38, wherein said lymphoma cell is a non-Hodgkin's lymphoma cell.

40. (Original) The method of claim 37, wherein said vector is a lentiviral vector.

41. (Original) The method of claim 37, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

42. (Original) The method of claim 37, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

43. (Cancelled).

44. (Currently amended) A method of treating a subject with a lymphoma comprising a bcl-6-expressing lymphoma cell, comprising contacting said subject with a vector expressing a nucleic acid molecule corresponding to ~~all or portion of~~ the sequence set forth in SEQ ID NO: 6, thereby treating ~~a~~ said subject with said lymphoma ~~cancer comprising a bcl-6-expressing cell~~.

45. (Original) The method of claim 44, wherein said lymphoma is a non-Hodgkin's lymphoma.

46. (Original) The method of claim 44, wherein said vector is a lentiviral vector.

47. (Original) The method of claim 44, wherein said nucleic acid molecule is a short interfering ribonucleic acid (siRNA) molecule.

48. (Original) The method of claim 44, wherein said nucleic acid molecule is a short hairpin RNA (shRNA) molecule.

49. (Cancelled).

50. (Withdrawn) An isolated nucleic acid molecule having a sequence selected from the sequences set forth in SEQ ID No: 1-10.

51. (Withdrawn) An oligo-deoxyribonucleic acid (ODN) molecule having a sequence corresponding to the isolated nucleic acid molecule of claim 50 or a fragment thereof, wherein said fragment is about 21-23 nucleotide in length.

52. (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim 50.

53. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 50.

54. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 50.

55. (Withdrawn) An isolated nucleic acid molecule having a sequence complementary to a sequence selected from the sequences set forth in SEQ ID No: 1-10.

56. (Withdrawn) A short interfering ribonucleic acid (siRNA) molecule having a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 21-23 nucleotide in length.

57. (Withdrawn) A short hairpin RNA (shRNA) molecule comprising a sequence corresponding to a fragment of the isolated nucleic acid molecule of claim 55, wherein said fragment is about 19-23 nucleotide in length.

58. (Withdrawn) A composition comprising the isolated nucleic acid molecule of claim 55.

59. (Withdrawn) A vector comprising the isolated nucleic acid molecule of claim 55.

60. (Withdrawn) A cell comprising the isolated nucleic acid molecule of claim 55.

61. (New) The method of claim 6, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

62. (New) The method of claim 11, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

63. (New) The method of claim 15, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

64. (New) The method of claim 21, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

65. (New) The method of claim 26, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

66. (New) The method of claim 32, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

67. (New) The method of claim 37, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.

68. (New) The method of claim 44, wherein said contacting reduces the amount of the bcl-6 protein expressed by said bcl-6-expressing cell or of a ribonucleic acid (RNA) molecule encoding said bcl-6 protein.